HR20013

· Fujian Shengdi Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HR20013, covering 2023-10-27 to 2025-11-17. Get the full timeline:

Most recent: Clinical Trial Update: HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents [Phase 3]